Peter Sasieni research projects
Cancer Prevention: Cervical Screening & HPV ControlFunding period: 01 April 2009 to 31 March 2014
Funding scheme: Population Research Committee - Programme Award
Funding committee: Population Research Committee
Background and relevance
Cervical cancer remains a major cause of mortality globally. Despite the success of screening, there are still ~2750 cervical cancers annually in the UK: coverage is falling and the underlying risk of disease is increasing. HPV vaccination will have little impact for thirty years. HPV testing offers an interim solution both in the UK and in developing countries.
- Self-sampling to improve coverage and reduce costs of cervical screening
- HPV testing in primary screening
- Control of cervical cancer in developing countries
- Surveillance and modelling of cervical screening and HPV vaccination
- Strategies for enhancing HPV clearance
The clinical team will conduct trials of self-sampling and help evaluate new biomarkers via colposcopy. We will establish a mega-trial to rigorously evaluate HPV testing as the sole primary screening test. We will update our overview of HPV testing. We will analyse data from the Peruvian TATI trial and work with colleagues in Cervical Cancer Action to set up a study of mother-daughter screening-vaccination in a developing country. We will analyse the CRISP-1 trial of diindolylmethane in the prevention of cervical cancer and help to develop other protocols for cancer prevention.